Abstract
While several genetic and morphological markers are established and serve to guide therapy of acute myeloid leukaemia (AML), there is still profound need to identify additional markers to better stratify patients. CD105 (Endoglin) is a type I transmembrane protein reported to induce activation and proliferation of endothelial cells. In addition, CD105 is expressed in haematological malignancies and the vessels of solid tumours. Here, CD105 associates with unfavourable disease course, but so far no data are available on the prognostic relevance of CD105 in haematological malignancies. We here generated a novel CD105 antibody for analysis of expression and prognostic relevance of CD105 in a cohort of 62 AML patients. Flow cytometric analysis revealed substantial expression in the various AML FAB types, with FAB M3 type displaying significantly lower surface levels. Next we established a cut-off specific fluorescence level of 5.22 using receiver-operating characteristics, which allowed to group patients in cases with CD105lo and CD105hi surface expression and revealed that high CD105 expression correlated significantly with poor overall and progression free survival. In conclusion, we here identify CD105 expression as a novel prognostic marker in AML, which may serve to optimize follow up and treatment decisions for AML patients.
Highlights
While several genetic and morphological markers are established and serve to guide therapy of acute myeloid leukaemia (AML), there is still profound need to identify additional markers to better stratify patients
CD105 expression has been described in myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL) and AML21–23, but its prognostic relevance in these and other haematopoietic malignancies has not been assessed so far
The transforming growth factor (TGF)-beta co-receptor CD105 plays a major role in foetal, adult and malignant angiogenesis
Summary
While several genetic and morphological markers are established and serve to guide therapy of acute myeloid leukaemia (AML), there is still profound need to identify additional markers to better stratify patients. We here generated a novel CD105 antibody for analysis of expression and prognostic relevance of CD105 in a cohort of 62 AML patients. CD105 (Endoglin) is a type I transmembrane protein which serves as an auxiliary receptor within the transforming growth factor (TGF) beta signalling complex and induces activation and proliferation of endothelial cells[7,8]. CD105 expression has been described in myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL) and AML21–23, but its prognostic relevance in these and other haematopoietic malignancies has not been assessed so far. We here report on a newly generated CD105 antibody that was used to analyse CD105 expression in a cohort of 62 AML patients and identified a strong correlation of high CD105 expression with adverse disease outcome
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
